Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dalgarno

Showing results (461-470 of 479) with videos related to

Pageof 48
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analoguesRaji Sundaramoorthi, William C Shakespeare, Terence P Keenan, et al.
Small (Weinheim an Der Bergstrasse, Germany)|April 3, 2025
Chiral Lemniscate Formation in Magnetic Field Controlled Topological Fluid FlowsMatt Jellicoe, Zoe Gardner, Amjad E H Alotaibi, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2000
Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activityW Shakespeare, M Yang, R Bohacek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.
Journal of Medicinal Chemistry|January 11, 2013
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitorsAnna Kohlmann, Stephan G Zech, Feng Li, et al.
BMJ (Clinical Research Ed.)|February 14, 2023
Evaluation of effectiveness and safety of pharmacist independent prescribers in care homes: cluster randomised controlled trialRichard Holland, Christine Bond, David P Alldred, et al.
Bone|February 13, 2001
Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorptionS M Violette, W Guan, C Bartlett, et al.
Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.
G3 (Bethesda, Md.)|June 23, 2022
Genomics analysis of Drosophila sechellia response to Morinda citrifolia fruit dietZachary Drum, Stephen Lanno, Sara M Gregory, et al.
Chemical Biology & Drug Design|January 9, 2008
SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activityWilliam C Shakespeare, Yihan Wang, Regine Bohacek, et al.
Pageof 48

Showing results (461-470 of 479) with videos related to

Sort By:
Pageof 48
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analoguesRaji Sundaramoorthi, William C Shakespeare, Terence P Keenan, et al.
Small (Weinheim an Der Bergstrasse, Germany)|April 3, 2025
Chiral Lemniscate Formation in Magnetic Field Controlled Topological Fluid FlowsMatt Jellicoe, Zoe Gardner, Amjad E H Alotaibi, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2000
Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activityW Shakespeare, M Yang, R Bohacek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.
Journal of Medicinal Chemistry|January 11, 2013
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitorsAnna Kohlmann, Stephan G Zech, Feng Li, et al.
BMJ (Clinical Research Ed.)|February 14, 2023
Evaluation of effectiveness and safety of pharmacist independent prescribers in care homes: cluster randomised controlled trialRichard Holland, Christine Bond, David P Alldred, et al.
Bone|February 13, 2001
Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorptionS M Violette, W Guan, C Bartlett, et al.
Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.
G3 (Bethesda, Md.)|June 23, 2022
Genomics analysis of Drosophila sechellia response to Morinda citrifolia fruit dietZachary Drum, Stephen Lanno, Sara M Gregory, et al.
Chemical Biology & Drug Design|January 9, 2008
SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activityWilliam C Shakespeare, Yihan Wang, Regine Bohacek, et al.
Pageof 48